30/07/24
https://www.globenewswire.com/news-release/2024/07/30/2920884/0/en/Dosing-completed-in-115-participant-bioavailability-bioequivalence-clinical-trial-for-proprietary-sleep-apnea-drug-candidate-IHL-42X.html
Incannex Completes Dosing in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X
- IHL-42X is a fixed dose combination drug targeting sleep apnea, a medical condition with no available registered pharmaceutical treatment for millions of sufferers in the USA alone.- bioavailability/bioequivalence (‘BA/BE’) clinical trial assessed the pharmacokinetics and tolerability of IHL-42X consistent with FDA development plan.
- Analysis of data underway, however, no serious adverse events were reported.
- Phase 2/3 FDA IND-enabling RePOSA clinical trial continues after dosing commenced in May 2024.
